Research Article
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles
Published Online:9 May 2013https://doi.org/10.2217/nnm.12.134
Abstract
Aim: Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are: actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. Materials & methods: Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices. Results: I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2. Conclusion: The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.
Original submitted 24 February 2012; Revised submitted 21 June 2012; Published online 17 October 2012
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
References
- 1 Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer5(1),65–72 (2005).
- 2 Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov.8(2),111–128 (2009).
- 3 Lehar J, Krueger AS, Avery W et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol.27(7),659–666 (2009).
- 4 Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther.5(7),1854–1863 (2006).
- 5 Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer7(8),573–584 (2007).
- 6 Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov.4(4),307–320 (2005).
- 7 Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem. Rev.107(5),1387–1407 (2007).
- 8 Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res.8(3),641–661 (2002).
- 9 Tardi PG, Dos Santos N, Harasym TO et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther.8(8),2266–2275 (2009).▪ Demonstrates that a specific drug combination of irinotecan and cisplatin could be antagonistic, additive or synergistic depending on the administered drug ratio.
- 10 Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med.346(2),85–91 (2002).
- 11 Hanna N, Bunn PA Jr, Langer C et al. Randomized Phase-III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol.24(13),2038–2043 (2006).
- 12 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2(12),751–760 (2007).▪▪ Excellent review on nanotechnology, specifically nanoparticles for cancer therapy.
- 13 Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res.44(10),1123–1134 (2011).
- 14 Hrkach J, Von Hoff D, Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med.4(128),128ra39 (2012).
- 15 Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev.41(7),2971–3010 (2012).
- 16 Hu C, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv.1(2),323–334 (2010).▪▪ Excellent review on the use of nanoparticles for combination chemotherapy. It discusses the advantages of using nanoparticles for combination chemotherapy and summarizes previous work carried out in the field.
- 17 Kolishetti N, Dhar S, Valencia PM et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl Acad. Sci. USA107(42),17939–17944 (2010).▪▪ Shows coencapsulation and delivery of two drugs with different chemical and physical properties in the same nanoparticle.
- 18 Maresca KP, Hillier SM, Femia FJ et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem.52(2),347–357 (2009).
- 19 Hillier SM, Maresca KP, Femia FJ et al. Preclinical evaluation of novel glutamate–urea–lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res.69(17),6932–6940 (2009).
- 20 Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials28(5),869–876 (2007).
- 21 Karnik R, Gu F, Basto P et al. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett.8(9),2906–2912 (2008).▪ First publication where polymeric poly(d,l-lactide-co-glycolide)-co-poly(ethylene glycol) nanoparticles were prepared in microfluidic devices.
- 22 Valencia PM, Basto PA, Zhang L et al. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano4(3),1671–1679 (2010).
- 23 Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther.7(6),974–982 (2008).
- 24 Thomas M, Kularatne SA, Qi L et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci.1175,32–39 (2009).
- 25 Kularatne SA, Wang K, Santhapuram HK, Low PS. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm.6(3),780–789 (2009).
- 26 Zastre J, Anantha M, Ramsay E, Bally M. Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother. Pharmacol.60(1),91–102 (2007).▪ Important publication where several references related to previous investigations on the synergism between irinotecan and cisplatin are provided together with an elucidation of the potential mechanism for their synergistic effect.
- 27 Gu FX, Karnik R, Wang AZ et al. Targeted nanoparticles for cancer therapy. Nano Today2(3),14–21 (2007).
- 28 Valencia PM, Hanewich-Hollatz MH, Gao W et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials32(26),6226–6233 (2011).
- 29 Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug–PLGA–PEG nanoparticles. Proc. Natl Acad. Sci. USA105(45),17356–17361 (2008).
- 30 Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC, Karnik R. Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv. Mater.23(12),H79–H83 (2011).
- 31 Vauthier C, Schmidt C, Couvreur P. Measurement of the density of polymeric nanoparticulate drug carriers by isopycnic centrifugation. J. Nanoparticle Res.1,411–418 (1999).
- 32 Johnson BK, Prud’homme RK. Mechanism for rapid self-assembly of block copolymer nanoparticles. Phys. Rev. Lett.91(11),118302 (2003).
- 33 Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv.1(4),321–333 (2004).
- 34 Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev.58(3),621–681 (2006).
- 35 Reese DM, Tchekmedyian S, Chapman Y, Prager D, Rosen PJ. A Phase-II trial of irinotecan in hormone-refractory prostate cancer. Invest. New Drugs16(4),353–359 (1998).
